Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brazil Pre-Vaccination survey gauges chikungunya immunity

NCT ID NCT07163845

Knowledge-focused Sponsor: Valneva Austria GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test over 5,300 people in about 10 Brazilian municipalities for antibodies to the chikungunya virus before a pilot vaccination campaign with the VLA1553 vaccine. The goal is to see how many people have already been exposed to the virus and how that might affect vaccine uptake. Participants are healthy individuals aged 2 and older living in selected areas.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help public health officials better plan vaccination campaigns against chikungunya in Brazil.
What could go wrong
This is an observational study, not a treatment trial. It only measures existing immunity and does not test the vaccine itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5,354 people

The number who actually took part.

Started

Sep 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population will consist of individuals ≥2 years of age residing in the municipalities where the pilot VLA1553 vaccination strategy will take place and who meet the eligibility criteria

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individuals residing in the selected municipalities of Brazil where the VLA1553 pilot vaccination strategy will be implemented. 2. Individuals ≥2 years of age 3. Individuals who sleep 3 nights a week or more in a household that is selected by cluster sampling. Exclusion Criteria: 1\. Individuals or their legally accepted representatives (LAR) who are not willing or not able to provide informed consent (and assent, as required) according to country-specific procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chikungunya virus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chikungunya

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chikungunya virus infection

Contacts and locations

Locations

  • Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus

    Laranjeiras, Sergipe, 49060-025, Brazil

  • Fundação Faculdade Regional De Medicina De São José Do Rio Preto

    São Pedro, São Paulo, 15090-000, Brazil

  • Universidade Federal Do Ceará

    Fortaleza, Ceará, 60430-160, Brazil

  • Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras

    Belo Horizonte, Minas Gerais, 31270-901, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.